These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 27201705

  • 1. New Observer-Reported Outcomes To Measure Treatment Satisfaction, Compliance, Palatability, and Gi Symptoms for Patients Needing Iron-Chelation Therapy.
    Lasch K, Horodniceanu EG, Carter JA, Dhatt H, Bal V, Côté I, Constantinovici N, Herranz RM, Malet I.
    Value Health; 2014 Nov; 17(7):A534-5. PubMed ID: 27201705
    [No Abstract] [Full Text] [Related]

  • 2. Modification of Patient Reported Outcomes Measures of Compliance, Gastrointestinal Symptoms, Palatability and Treatment Satisfaction for Patients Needing Iron Chelation therapy.
    Lasch K, Côté I, Roma T, Srivastava B, Horodniceanu EG, Dhatt H, Carter JA, Bal V.
    Value Health; 2014 Nov; 17(7):A574. PubMed ID: 27201926
    [No Abstract] [Full Text] [Related]

  • 3. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 4. A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major.
    Elalfy MS, Massoud W, Elsherif NH, Labib JH, Elalfy OM, Elaasar S, von Mackensen S.
    Pediatr Blood Cancer; 2012 Jun; 58(6):910-5. PubMed ID: 22232075
    [Abstract] [Full Text] [Related]

  • 5. The palatability and tolerability of deferasirox taken with different beverages or foods.
    Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E.
    Pediatr Blood Cancer; 2013 Sep; 60(9):1507-12. PubMed ID: 23637051
    [Abstract] [Full Text] [Related]

  • 6. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.
    Hemoglobin; 2014 Sep; 38(2):111-4. PubMed ID: 24351163
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I.
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [Abstract] [Full Text] [Related]

  • 8. Effective iron chelation practice for patients with β-thalassemia major.
    Carson SM, Martin MB.
    Clin J Oncol Nurs; 2014 Feb; 18(1):102-11. PubMed ID: 24476732
    [Abstract] [Full Text] [Related]

  • 9. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Feb; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 10. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 11. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
    Osborne RH, De Abreu Lourenço R, Dalton A, Houltram J, Dowton D, Joshua DE, Lindeman R, Ho PJ.
    Value Health; 2007 Oct; 10(6):451-6. PubMed ID: 17970927
    [Abstract] [Full Text] [Related]

  • 12. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Oct; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 13. Treatment of iron overload in thalassemia.
    Cianciulli P.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [Abstract] [Full Text] [Related]

  • 14. Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations.
    Nolte F, Angelucci E, Breccia M, Gattermann N, Santini V, Vey N, Hofmann WK.
    Leuk Res; 2015 Oct; 39(10):1028-33. PubMed ID: 26293555
    [Abstract] [Full Text] [Related]

  • 15. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Oct; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 16. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V, Kurtoglu E.
    Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
    [Abstract] [Full Text] [Related]

  • 17. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Jan; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 18. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
    Thuret I, Hacini M, Pégourié-Bandelier B, Gardembas-Pain M, Bisot-Locard S, Merlat-Guitard A, Bachir D.
    Hematology; 2009 Dec; 14(6):315-22. PubMed ID: 19941737
    [Abstract] [Full Text] [Related]

  • 19. Traumatized refugees: morbidity, treatment and predictors of outcome.
    Buhmann CB.
    Dan Med J; 2014 Aug; 61(8):B4871. PubMed ID: 25162447
    [Abstract] [Full Text] [Related]

  • 20. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
    Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G, IRON-2 Study Group.
    Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.